Clinical features and treatment outcome of 14 patients with primary pulmonary mucosa-associated lymphoid tissue lymphoma

房辉,李晔雄,宋永文,王维虎,金晶,任骅,王淑莲,刘跃平

DOI: https://doi.org/10.3760/cma.j.issn.1004-4221.2014.01.004

2014-01-01

Abstract:Objective To analyze the clinical features and prognosis of patients with primary pulmonary mucosa-associated lymphoid tissue (MALT) lymphoma.Methods A retrospective analysis was performed on the clinical data of 14 patients with primary pulmonary MALT lymphoma between 1999 and 2012.Eight patients had Ann Arbor stage Ⅰ E disease,5 had stage Ⅱ E disease,and 1 had stage Ⅲ E disease.Overall,patients were treated with surgery alone (n =4),surgery followed by radiotherapy or chemotherapy (n =5),chemotherapy plus radiotherapy (n =3),or chemotherapy alone (n =2).Results The median age at diagnosis was 55 years.The male-to-female ratio was 1 ∶ 1.33.With a median follow-up of 48.3 months,no patient died during follow-up,but 3 patients had recurrence in the lungs,mediastinal lymph nodes,and right lung and meninges at 24.5,28.5,and 36.5 months,respectively,after treatment.The 2-and 4-year progression-free survival rates were 91％ and 69％,respectively.Conclusions Primary pulmonary MALT lymphoma is indolent,and most patients show a good response to treatment.Clinical treatment should be selected according to the lesion and patient's condition.